IL-17 RA & IL-17 RC

IL-17 RA & IL-17 RC Overview

English Name	Interleukin-17 receptor A	Approved Drugs	1
Drugs in Clinical Trials	2	Target Synonym	CDw217，IL-17 receptor A，IL17R，IL17RA，Interleukin 17 Receptor A，IL-17RA，Interleukin 17 Receptor，CD217 Antigen，HIL-17R，CANDF5，CD217，IMD51，Interleukin-17 receptor A
Highest Development Stage	Approved

English Name	Interleukin-17 receptor A
Target Synonym	CDw217，IL-17 receptor A，IL17R，IL17RA，Interleukin 17 Receptor A，IL-17RA，Interleukin 17 Receptor，CD217 Antigen，HIL-17R，CANDF5，CD217，IMD51，Interleukin-17 receptor A
Approved Drugs	1
Drugs in Clinical Trials	2
Highest Development Stage	Approved

IL-17 RA & IL-17 RC Product List

Product Category
Protein (1)Cell (1)
Product Status
Launched (2)
Species
Human (2)
Tag
Fc Tag (1)- (1)
Conjugate
Unconjugated (1)- (1)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature	Order Now
CHEK-ATF133	Human	HEK293	Human IL-17 RA/IL-17 RC (Luc) HEK293 Reporter Cell				Add to Cart
ILC-H5257	Human	HEK293	Human IL-17 RA&IL-17 RC Heterodimer Protein, Fc Tag&Fc Tag (MALS verified)				Add to Cart

Total: 2

IL-17 RA & IL-17 RC Background

Also binds heterodimers formed by IL17A and IL17F as part of a heterodimeric complex with IL17RC. Cytokine binding triggers homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter, leading to TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways, ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation.

IL-17 RA & IL-17 RC Synonyms

IL-17 RA & IL-17 RC,IL-17RA & IL-17RC,CD217 & IL-17 RC

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
XCUR-17	XCUR-17	Phase 1 Clinical	Exicure Inc	Psoriasis	Details
PN-881	PN-881	Phase 1 Clinical	Protagonist Therapeutics Inc	Dermatitis; Psoriasis	Details

Marketed Drug Information

English Name	Research Code	Highest Development Stage	Company	Earliest Brand Name	Earliest Approval Country	Earliest Indication	Earliest Approval Company	Earliest Approval Date	Indication	Clinical Trial
Brodalumab	AMG-827; KHK-4827; IL-17R mAb; MEDI-6365	Approved	Amgen Inc	Siliq, Lumicef, Kyntheum, 立美芙	Japan	Psoriasis; Arthritis, Psoriatic	Kyowa Kirin Co Ltd	2016-07-04	Arthritis, Psoriatic; Arthritis, Rheumatoid; Asthma; Axial Spondyloarthritis; Brain Neoplasms; Breast Neoplasms; Colonic Neoplasms; Crohn Disease; Esophageal Neoplasms; Genital Neoplasms, Female; Head and Neck Neoplasms; Hidradenitis Suppurativa; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Mouth Neoplasms; Non-radiographic axial spondyloarthritis; Palmoplantar pustulosis; Pancreatic Neoplasms; Plaque psoriasis; Prostatic Neoplasms; Psoriasis; Pustular psoriasis; Rectal Neoplasms; Scleroderma, Systemic; Skin Neoplasms; Solid tumours; Spondylitis, Ankylosing; Stomach Neoplasms; Testicular Neoplasms; Thyroid Neoplasms	Details